

AD _____

Award Number: DAMD17-95-2-5012

TITLE: Postdoctoral Research Associateship Program with USAMRMC

PRINCIPAL INVESTIGATOR: Judith Nyquist, Ph.D.

CONTRACTING ORGANIZATION: National Academy of Sciences
Washington, DC 20418

REPORT DATE: February 2003

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

20030416 258

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE	3. REPORT TYPE AND DATES COVERED	
	February 2003	Final (4 Sep 95 - 28 Feb 03)	
4. TITLE AND SUBTITLE Postdoctoral Research Associateship Program with USAMRMC			5. FUNDING NUMBERS DAMD17-95-2-5012
6. AUTHOR(S): Judith Nyquist, Ph.D.			
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) National Academy of Sciences Washington, DC 20418 Email: jnyquist@nas.edu			8. PERFORMING ORGANIZATION REPORT NUMBER
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER
11. SUPPLEMENTARY NOTES			
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) none provided			
14. SUBJECT TERMS: research candidates			15. NUMBER OF PAGES 31
			16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited

Table of Contents

Cover.....	i
SF 298.....	ii
Table of Contents.....	iii
Publicity	1
Requests	1
Competition, Applications, Citizenship	2
Associates' Activities	3
Attachments/Appendix.....	4

THE NATIONAL ACADEMIES
Advisers to the Nation on Science, Engineering, and Medicine

**National Research Council
RESEARCH ASSOCIATESHIP PROGRAM**

with the

**U.S. Army Medical Research Materiel Command
(AMRMC)**

Contract number: DAMD17-95-2-5012

Publicity

The National Academies Research Associateship Programs for the report period were announced to the scientific community in the fall of the preceding year, 2001. Publicity materials describing the National Research Council-U.S. Army Medical Research Materiel Command (AMRMC). Programs were distributed in November to presidents, graduate deans, and heads of appropriate science and engineering departments and minority-affairs offices of all academic degree-granting institutions in the United States. An e-mail announcement of the programs was sent to these same contact points prior to each review deadline. Promotional materials were sent to Laboratory Program Representatives, Associateship Advisers, and other interested persons. General advertisements of programs were placed in leading scientific and engineering publications. Publicity materials and other related information were made available on the internet. Research Associateship Programs staff attended numerous society meetings and minority recruitments to promote the various programs and meet with prospective applicants throughout the year.

Requests

Application materials were distributed in response to specific requests for information about the AMRMC Research Associateship Program or as a result of general requests by persons whose fields of specialization appeared to be appropriate for the research opportunities available in the AMRMC laboratories.

Competition

Panel reviews of applicants for the Research Associateship Programs, including those with the U.S. Army Medical Research Materiel Command, are conducted in winter, spring, summer, autumn of each year. The following is a breakdown of the action taken with the applications during the report period.

	review-year			
	<u>winter-02</u>	<u>autumn- 02</u>	<u>spring- 03</u>	<u>TOTAL</u>
TOTAL APPLICATIONS				
Number of Applications Reviewed	4	12	12	28
Applications not recommended (did not pass Review)	2	1	1	4
Applications Recommended (passed Review)	2	11	11	24
Awards offered	0	9	0	9
Awards accepted	0	5	0	5
Awards declined	0	3	0	3
Awards withdrawn by RAP (NRC officially withdrew award <i>after</i> it had been accepted.)	0	1	0	1

Associates' Citizenship

Associates on tenure between 10/1/2002 and 2/28/2003 were citizens or Permanent Residents of the United States and the following countries:

2	Australia	1	Italy
1	Bangladesh	3	People's Republic of China
1	Denmark	1	Poland
1	Hungary	4	Russia
4	India	1	Ukraine
1	Israel	25	United States

Associates' Activities

Associates who ended tenure during the report period were on tenure for an average of **29** months, ranging from **24** months to **39** months.

Of the **5** Associates who ended tenure during the report period, **4 (80%)** submitted final reports. In the final reports, Associates indicated the following scholarly activity while on tenure.

7 Articles published in refereed journals
1 Patent applications

4 International presentations
10 Domestic presentations
1 Awards

After ending their tenure, Associates indicated their future plans as follows:

2 Remain at host agency as perm. employee
- Remain at host agency as contract employee
- Research position at other US gov't. lab
- Administrative position at US gov't. lab
- Research position at foreign gov't. lab
- Research/teaching-US college/university

- Research/teaching-foreign college/university
- Research/admin in industry
- Research/admin in non-profit organization
- Postdoctoral research
1 Self employed
1 Other (may include unemployed)

In their final reports, Associates were asked to evaluate certain aspects of their experiences on a scale of 1 (low) to 10 (high). The average rating for each item follows:

- *Short-term value:* Development of knowledge, skills, and research productivity
- *Long-term value:* How your Research Associateship affected your career to date
8.5 *Laboratory:* Quality of the support you received from the federal laboratory
9.8 *RAP:* Quality of the support you received from the Research Associateship Programs

Advisers also were asked to complete an evaluation of the Associate. The following summarizes the Adviser evaluations for Associates ending tenure during the report period. Of the **5** Associates who ended tenure, **2 (40%)** Adviser evaluations were completed. Assessments were made on six criteria using the following rating scale: 1-below average, 2-average, 3-above average, 4-good, and 5-outstanding/exceptional. The average rating for each item follows:

3.0 Knowledge of field
3.0 Innovative thinking
2.5 Research techniques

3.0 Independence
3.0 Motivation
3.0 Overall scientific ability

The Adviser was asked, "Would you like this Associate as a professional colleague?" The Advisers responded in the following manner:

1 Yes
1 No

- No Comment
- No Answer

Additional information about the Associates' activities can be found in the attachments described below and the Appendix.

Attachment 1: Associates who were on tenure between 10/1/2002 and 2/28/2003. Included are the Associate's laboratory center/division location, the starting and termination dates, and the names of their advisers. For those Associates who ended tenure during the report period, it is noted if the final and adviser evaluation reports have been received. Associates are required to submit final reports upon termination of tenure, and advisers are asked to submit a final evaluation of each Associate. Associates who have not submitted a final report have received follow-up correspondence.

Attachment 2: All recommended candidates by category (e.g., Recommended, Accepted, No Funding, Declined, etc.). This report includes information about citizenship, Ph.D. institution, title of proposed research, proposed or actual starting date, and adviser.

Attachment 3: Summaries of Associate patent activity, if any, and Associate research during tenure as reported on the Associates' termination reports. The summary of patent activity includes the patent application title, inventor(s), and date of application.

Appendix: Final reports received from the Associates who ended tenure during the report period.

Associates On Tenure**10/1/2002 - 2/28/2003****Attachment 1****AMRMC - U.S. Army Medical Research Institute of Chemical Defense**

3/26/2003 Page 1 of 4

Associate Name+ Adviser	Division	Tenure Dates Start/End	Termination Report	Adviser Report
Petrikovics, Ilona <i>Dr. Steven I. Baskin</i>	(S) Pharmacology Division	1/3/2003 - 1/2/2004		

1 Associates Listed

*** End of Center ***

+ (S) indicates the associate was a Senior.

Highlighted entries indicate no entry on the Award Init Screen but data on the Post Tenure Screen.

Associates On Tenure**10/1/2002 - 2/28/2003****Attachment 1****AMRMC - U.S. Army Medical Research Institute of Infectious Diseases**

3/26/2003 Page 2 of 4

Associate Name+ Adviser	Division	Tenure Dates Start/End	Termination Report	Adviser Report
Keller, Michael Anthony <i>Dr. Alan L. Schmaljohn</i>	Virology Division	12/9/2002 - 12/8/2003		

1 Associates Listed

*** End of Center ***

+ (S) indicates the associate was a Senior.

Highlighted entries indicate no entry on the Award Init Screen but data on the Post Tenure Screen.

Associates On Tenure**10/1/2002 - 2/28/2003****Attachment 1****AMRMC - U.S. Army Research Institute of Environmental Medicine**

3/26/2003 Page 3 of 4

Associate Name+ Adviser	Division	Tenure Dates Start/End	Termination Report	Adviser Report
Weyand, Peter Gregory <i>Dr. Reed W. Hoyt</i>	(S) Divison not specified	9/20/1999 - 12/31/2002	Not Recd	Not Recd

1 Associates Listed

*** End of Center ***

+ (S) indicates the associate was a Senior.

Highlighted entries indicate no entry on the Award Init Screen but data on the Post Tenure Screen.

Associates On Tenure**10/1/2002 - 2/28/2003****Attachment 1****AMRMC - Walter Reed Army Institute of Research**

3/26/2003 Page 4 of 4

Associate Name+ Adviser	Division	Tenure Dates Start/End	Termination Report	Adviser Report
Chen, Yue-Qin <i>Dr. Peter K. Chiang</i>	(S) Division Of Experimental Therapeutics	2/11/2003 - 2/10/2004		
Fleming, Sherry D. <i>Dr. George C. Tsokos</i>	Division Of Medicine	1/2/2001 - 1/1/2003	Received	Not Recd
Leader, Haim Nissan <i>Dr. Richard K. Gordon</i>	(S) Division Of Biochemistry	11/4/2002 - 5/3/2003		
Miroshnikova, Olga Vyatcheslavovna <i>Dr. Ai J. Lin</i>	Division Of Experimental Therapeutics	2/25/2003 - 2/24/2004		
Nair, Lalitha Punchayil Velayudhan <i>Dr. David E. Lanar</i>	(S) Division Of Commun Diseases/Immunology	10/11/2000 - 10/10/2000	Received	Not Recd
Savransky, Vladimir <i>Dr. Jeenan Tseng</i>	(S) Division Of Pathology	2/12/2001 - 2/11/2003	Received	Received
Thakur, Suman Siddharth <i>Dr. Bhupendra P. Doctor</i>	Division Of Biochemistry	1/18/2002 - 11/17/2002		
Zhu, Shuren <i>Dr. Ai J. Lin</i>	Division Of Experimental Therapeutics	11/1/1999 - 10/31/2002	Received	Received

8 Associates Listed

*** End of Center ***

+ (S) indicates the associate was a Senior.

Highlighted entries indicate no entry on the Award Init Screen but data on the Post Tenure Screen.

Recommended Candidates 10/1/2002 - 2/28/2003
AMRMC- U.S. Army Institute of
Surgical Research

Attachment 2

3/26/2003 Page 1 of 7

February 2003

1- Recommended

WENKE, JOSEPH C

Ph.D. Date: 2003

Citizenship: United States

Texas A&M University

Adviser: Dr. Victor A. Convertino

Research Field: Physiology

Research Title: Antimicrobial Bone Graft Substitutes

* * *

Recommended Candidates 10/1/2002 - 2/28/2003
AMRMC- U.S. Army Medical
Research Institute of Chemical
Defense

Attachment 2

3/26/2003 Page 2 of 7

October 2002

A- Accepted Award

LANGSTON, JEFFREY L	Ph.D. Date: 2002
Citizenship: United States	Auburn University/AL
Adviser: Dr. Maurice L. Sipos	Expected Starting Date: 5/05/03
Research Field: Neurotoxicology	Termination Date: 5/04/04
Research Title: Development of a Guinea Pig Test Battery to Assess the Behavioral Effects of Exposure to Chemical Warfare Nerve Agents	

February 2003

1- Recommended

JUNG, BRUCE J	Ph.D. Date: 2000
Citizenship: United States	University of Florida
Adviser: Dr. Tsung-Ming A. Shih	
Research Field: Neurotoxicology	
Research Title: Effects of Repeated Low Dose VX Exposure on Neurobehavior, EEG Spectrum, and Extracellular Neurotransmitter Levels	

* * *

Recommended Candidates 10/1/2002 - 2/28/2003
AMRMC- U.S. Army Medical
Research Institute of Infectious
Diseases

Attachment 2

3/26/2003 Page 3 of 7

October 2002

1- Recommended

RHOADES, ELIZABETH R Ph.D. Date: 1997
Citizenship: United States Colorado State University
Adviser: Dr. Sina Bavari
Research Field: Immunology
Research Title: Identification of Human MHC Class II-Restricted Epitopes of the Protective antigen (PA) and Novel Correlates of Immunity

A- Accepted Award (2 Applicants listed)

FRITZ, ELIZABETH A Ph.D. Date: 2002
Citizenship: United States Rush University/IL
Adviser: Dr. Peter B. Jahrling Actual Starting Date: 3/03/03
Research Field: Virology Termination Date: 3/02/04
Research Title: Modulation of the Immune Response During Smallpox and Monkeypox Infections

KELLER, MICHAEL A Ph.D. Date: 2002
Citizenship: United States Wake Forest University/NC
Adviser: Dr. Alan L. Schmaljohn Actual Starting Date: 12/09/02
Research Field: Virology Termination Date: 12/08/03
Research Title: Therapeutic Targeting of Filovirus RNA-Dependent RNA Polymerase

8- Declined (3 Applicants listed)

ELLISON, MICHAEL A Ph.D. Date: 2002
Citizenship: United States University of Utah
Adviser: Dr. Leonard A. Smith
Research Field: Biochemistry
Research Title: Development of Vaccines Against Botulinum Neurotoxin Type G

GARRUS, JENNIFER E Ph.D. Date: 2002
Citizenship: United States University of Utah
Adviser: Dr. Sina Bavari
Research Field: Virology
Research Title: Late Domain Mediated Filovirus Budding

MARIANS, RUSSELL C Ph.D. Date: 2001
Citizenship: United States Mt Sinai School of Medicine-CUNY
Adviser: Dr. Bradford Powell
Research Field: Bacteriology
Research Title: Characterizing the Immune Response to the F1-V Y.Pestis Vaccine

Recommended Candidates 10/1/2002 - 2/28/2003
AMRMC- U.S. Army Medical
Research Institute of Infectious
Diseases

Attachment 2

3/26/2003 Page 4 of 7

February 2003

1- Recommended (6 Applicants listed)

CURTIS, KRISTOPHER M	Ph.D. Date: 2003
Citizenship: United States	U of North Carolina-Chapel Hill
Adviser: Dr. Peter B. Jahrling	
Research Field: Molecular Virology	
Research Title: Utilization of an Ebola Reverse Genetics System to Identify Critical Mechanisms in Disease Pathogenesis	
DUPUY, LESLEY C, JR	Ph.D. Date: 1999
Citizenship: United States	University of South Alabama
Adviser: Dr. Connie S. Schmaljohn	
Research Field: Molecular Virology	
Research Title: Evaluation of Multivalent DNA Vaccine Strategies for Encephalytic Alphavirus Immunization	
EVANS, JARED D	Ph.D. Date: 2002
Citizenship: United States	State U of New York-Stony Brook
Adviser: Dr. Sina Bavari	
Research Field: Virology	
Research Title: Late Domain Functions in Filovirus Budding	
HINCKLEY, MIDDLETON B	Ph.D. Date: 2003
Citizenship: United States	University of Notre Dame/IN
Adviser: Dr. John H. Carra	
Research Field: Biochemistry	
Research Title: Ebola Virus Assembly and Budding at the Plasma Membrane	
O'BRIEN, DAVID K	Ph.D. Date: 2003
Citizenship: United States	Virginia Polytech Inst & State U
Adviser: Dr. Arthur M. Friedlander	
Research Field: Microbiology	
Research Title: Effect of Capsule on Innate Immunity to Anthrax	
PEARSON, BROOKE	Ph.D. Date: 2003
Citizenship: United States	Brown University/RI
Adviser: Dr. Arthur M. Friedlander	
Research Field: Immunology	
Research Title: Characterization of the Antibody Response to Inhalational Anthrax in Humans	

Recommended Candidates 10/1/2002 - 2/28/2003
AMRMC- U.S. Army Research
Institute of Environmental
Medicine

Attachment 2

3/26/2003 Page 5 of 7

February 2003

1- Recommended

JAY, OLIVER E Ph.D. Date: 2002
Citizenship: England, U.K. Loughboro U Tech
Adviser: Dr. John W. Castellani
Research Field: Physiology and Biophysics
Research Title: Predicting Operational Performance During Cold Water Immersion

* * *

Recommended Candidates 10/1/2002 - 2/28/2003
AMRMC- Walter Reed Army
Institute of Research

Attachment 2

3/26/2003 Page 6 of 7

October 2002

A- Accepted Award (3 Applicants listed)

KUBATA, BRUNO K Ph.D. Date: 1998
Citizenship: Congo Osaka City University/Japan
Adviser: Dr. Samuel K. Martin Expected Starting Date: 3/31/03
Research Field: Molecular Pathology Termination Date: 3/30/04
Research Title: The Role of Arachidonic Acid Metabolites in the Life Cycle and Pathogenesis of Parasitic Protozoa

SALLUM, MARIA A Ph.D. Date: 1994
Citizenship: Brazil Sao Paulo, U
Adviser: Dr. Richard C. Wilkerson Expected Starting Date: 6/02/03
Research Field: Systematic Biology Termination Date: 6/01/04
Research Title: Systematic Revision and Phylogenetic Analysis of the Leucosphyrus Group of the Anopheles (Cellia) (Diptera: Culicidae)

THATHY, VANDANA Ph.D. Date: 2000
Citizenship: Kenya New York University
Adviser: Dr. Jose A. Stoute Expected Starting Date: 5/01/03
Research Field: Infectious Diseases Termination Date: 4/30/04
Research Title: Complement Receptor 1 Gene Polymorphisms and Severe Plasmodium falciparum Malaria

W- Withdrew after Review/Recommend

ABANULO, JUDE C Ph.D. Date: 2002
Citizenship: England, U.K. University of Southampton/Eng
Adviser: Dr. Richard K. Gordon
Research Field: Biotechnology
Research Title: Hand Held Cholinesterase Units

November 2002

1- Recommended (2 Applicants listed)

KADAR, TAMAR Ph.D. Date: 1989
Citizenship: Israel Technion-Israel Institute of Tech
Adviser: Dr. James M. Petras
Research Field: Neurotoxicology
Research Title: Effects of Low Dose Exposure of Organophosphates on Synaptic Plasticity in the Central Nervous System

KONGKASURIYACHAI, DARIN Ph.D. Date: 2003
Citizenship: Thailand Johns Hopkins University/MD
Adviser: Dr. Jetsumon P. Sattabongkot
Research Field: Infectious Diseases
Research Title: Molecular Mechanism of Relapsing Malaria: Identification of Hypnozoite Stage Antigens by Differential Display

Recommended Candidates 10/1/2002 - 2/28/2003
AMRMC- Walter Reed Army
Institute of Research

Attachment 2

3/26/2003 Page 7 of 7

February 2003

1- Recommended

SILMAN, HARRY I Ph.D. Date: 1964
Citizenship: Israel Weizmann Inst of Science/Israel
Adviser: Dr. Bhupendra P. Doctor
Research Field: Biochemistry
Research Title: Crystallization and Structure Determination of a Native Cholinesterase Tetramer

三 三 三

AMRMC- U.S. Army Medical Research and Materiel Comm:

Fleming, Sherry D.

1/02/2001 1/01/2003

1 Complement inhibitors can prevent local and systemic injury due to mesenteric ischemia/reperfusion (IR).

2 The anaphylotoxin C5a is critical for both local and systemic tissue damage.

3 The classical complement pathway is activated by natural antibodies in response to IR-induced damage.

4 IgM and IgG natural antibodies each contribute unique aspects of the tissue damage.

5 The natural antibody repertoire is altered in the absence of complement receptor 2 (CR2).

Nair, Lalitha Punchayil Velayudhan

10/11/2000 10/10/2002

1 Worked in the development of the purification of an important malaria vaccine target antigen PfAMA/E that (99% pure) was scaleable and transferable to GMP facility, and that induced high titre growth inhibitory antibodies in rabbits.

3 Purification protocol was used in the writing of Batch Production Record BPR-480, entitled "Preparation of a Bulk Lot Recombinant P. falciparum AMA1/E Protein Expressed in Escherichia coli, Origami Strain."

5 The data from this analysis will be part of an IND application to the FDA to use this protein as a vaccine in humans.

7 Cloned, expressed, purified and immunologically characterized all six subdomain constructs from ectodomain of AMA-1 in bacteria. It enabled to fine map the immunodominant regions of the whole molecule.

9 Erythrocyte binding activity of AMA-1 and the subdomain fragments is established from this study. This data may help to develop better AMA-1 based constructs for vaccine study.

Savransky, Vladimir

2/12/2001 2/11/2003

1 Developing the new murine intranasal SEB toxic shock model.

2 Screening various SEB mutant proteins for superantigenicity, toxicity, and selecting safe mucosal vaccine candidate.

AMRMC- U.S. Army Medical Research and Materiel Comm:

3 Studying immunogenecity and protective properties of selected candidates.

4 Developing a novel mucosal vaccine against SEB intoxication.

Zhu, Shuren

11/01/1999 10/31/2002

1 A novel class of peptidomimetic antimalarial agents has been discovered.

2 Compounds exhibited potent in vitro and in vivo activity against malarial parasites.

FINAL REPORT

Enter information electronically in Layout view.

Return this form directly to the NRC as an E-mail attachment, or print out and mail or fax.

1) Associate Last or Family Name Fleming	First Name Sherry	M.I. D	
2) FORWARDING Address (for tax statement / final stipend check) 11503 Regnid Dr. Silver Spring, MD 20902	FORWARDING Phone(s) and E-Mail (if known) phone: (301) 319-7359 phone: (301) 942-9440 e-mail: sfleming@usuhs.mil		
3) Today's Date	Dates of Tenure from January 2, 2001 to January 1, 2003		
4) Agency AMRMC	Laboratory or WRAIR/Tsokos	NASA Center NASA Ctr	Division / Branch / Directorate Cellular Injury/MCR

5) NAME OF RESEARCH ADVISER

George Tsokos

6) TITLE OF RESEARCH PROPOSAL

Role of natural antibodies and complement inhibitors in mesenteric ischemia-reperfusion injury

7) SUMMARY OF RESEARCH DURING TENURE Itemize significant findings in concise form, utilizing key concepts/words.

- 1) Complement inhibitors can prevent local and systemic injury due to mesenteric ischemia/reperfusion (IR)
- 2) The anaphylotoxin C5a is critical for both local and systemic tissue damage
- 3) The classical complement pathway is activated by natural antibodies in response to IR-induced damage.
- 4) IgM and IgG natural antibodies each contribute unique aspects of the tissue damage.
- 5) The natural antibody repertoire is altered in the absence of complement receptor 2 (CR2).

8) RESEARCH IN PROGRESS Describe in no more than 100 words.

I am continuing the CR2 studies to determine the antigen for the natural antibody recognition of ischemic tissue. In addition, the cell type that is secreting the natural antibodies and the recruitment of these cells to the local area are being investigating. The C5 project is being extended to determine the actual involvement of integrin a4 and VCAM in local and systemic injury.

9) PUBLICATIONS AND PAPERS RESULTING FROM NRC ASSOCIATESHIP RESEARCH

Provide complete citations: author(s), title, full name of journal, volume number, page number(s), and year of publication.

a) Publications in peer-reviewed journals

Fleming, S.D., Lambris, J.D., T.Shea-Donohue and G.C. Tsokos. 2002. C5 is critical for the mesenteric ischemia/reperfusion-induced local and remote organ injury. 2002. Clinical Immunol. In Press.

Fleming, S.D., T.Shea-Donohue, J.M. Guthridge, L. Kulik, T.J. Waldschmidt, M.G. Gipson, G.C. Tsokos and V.M. Holers. 2002. Mice deficient in complement receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody repertoire. J. Immunol.169:2126-2133.

Fleming, S.D., B. Starnes, J.G. Kiang, A. Stojadinovic, G.C. Tsokos, and T.Shea-Donohue. 2002. Heat stress protection against mesenteric ischemia/reperfusion -induced alterations in intestinal mucosa in rats. J. Applied Physiol. 92:2600-2607.

Rehrig, S., S.D. Fleming, J. Anderson, J.M. Guthridge, J. Rakstang, C. McQueen, V.M. Holers, G.C. Tsokos, and T.Shea-Donohue. 2001. Complement inhibitor, Crry-Ig attenuates intestinal damage after the onset of mesenteric ischemia/reperfusion injury in mice. J. Immunol. 167: 5921-5927.

b) Books, book chapters, other publications

Fleming, S.D. and G.C. Tsokos. 2001. Complement Inhibitors in Rheumatic Diseases in Modern therapeutics in Rheumatic Diseases. Pg 443-452. Ed. G.C. Tsokos, Humana Press, Totowa, NJ.

c) Manuscripts in preparation, manuscripts submitted

Karpel-Massler, G., Fleming, S.D., Kirschfink, M., Tsokos, G.C. 2002. Human C1 esterase inhibitor attenuates murine mesenteric ischemia/reperfusion induced local organ injury. Submitted. 2002.

Fleming, S.D., Lambris, J.D., and G. Tsokos. C5a-mediated mesenteric ischemia/reperfusion injury is independent of polymorphonuclear neutrophils.

Fleming, S.D., Anderson, J., Rehrig, S., Wilson, F., Shea-Donohue, T., and G. Tsokos. Systemic effects of Crry-Ig after mesenteric ischemia/reperfusion.

Anderson, J. Fleming, S.D., Rehrig, S., Tsokos, G., Shea-Donohue, T and M. Basta. Intravenous immunoglobulin attenuates mesenteric ischemia-reperfusion injury

10 PATENT OR COPYRIGHT APPLICATIONS RESULTING FROM NRC ASSOCIATESHIP RESEARCH

Provide titles, inventors, and dates of applications.

None

11) PRESENTATIONS AT SCIENTIFIC MEETINGS OR CONFERENCES

Provide complete references: author(s), title, abstract/proceeding citation, meeting name and location.

International

International Complement Society Meeting, Palermo, Italy, Sept. 2002. Fleming, SD, Lambris, JD, Shea-Donohue, T, and Tsokos, GC. C5a is responsible for the mesenteric ischemia/reperfusion-induced local and remote organ injury. Poster Presentation

International Complement Associated Disease, Animal Models and Therapeutic Workshop. Santorini, Greece. 2001. Fleming, SD, Lambris, JD, Shea-Donohue, T. and Tsokos, GC. C5a is responsible for the mesenteric ischemia/reperfusion-induced local and remote organ injury Abstract #20. Oral Presentation.

Domestic

AAATAC meeting, Florida, Sept. 2002, Oral Presentation.

AAATAC meeting, Florida, Sept. 2001

The C5a fragment of C5 is critical of the mesenteric ischemia/reperfusion-induced local and remote organ injury, Fleming, SD, Lambris, JD, Shea-Donohue, T and Tsokos, GC.

FOCIS Meeting, Boston, MA, 2001 Poster Presentation

C5 inhibitors prevent mesenteric ischemia/reperfusion induced injury. by Fleming, SD, Lambris, JD, Shea-Donohue, T. and Tsokos, GC. Clinical Immunology 99:175 Abstract #221.

12) SEMINARS OR LECTURES DELIVERED AT UNIVERSITIES AND/OR INSTITUTES Include dates, names and locations of seminars.

Research seminar. Dept. Pathology and Laboratory Medicine, Univ. Penn, Philadelphia, PA. March 2002

Immunology section, 4 lectures, Structure and Function of Organ Systems, Uniformed Services University of the Health Sciences, Bethesda, MD April 2002.

13) PROFESSIONAL AWARDS RECEIVED DURING TENURE

None

14) POST-TENURE POSITION TITLE

CRM Investigator

15) POST-TENURE ORGANIZATION Provide name and city of organization.

Clinical Research Management

Silver Spring, MD 20910

16) POST-TENURE POSITION STATUS / CATEGORY Please indicate only one.

Remain at Host Agency as Permanent Employee
 Remain at Host Agency as Contract/Temporary Employee
Abbreviate Host Laboratory/Center WRAIR
 Research Position at Another US Government Laboratory
 Administrative Position at US Government Laboratory
 Research Position at Foreign Government Laboratory

Research/Teaching at US College/University
 Research/Teaching at Foreign College/University
 Research/Administration in Industry
 Research/Admin in Non-Profit Organization
 Postdoctoral Research
 Self Employed
 Other: specify _____

17) APPRAISAL OF THE ASSOCIATESHIP PROGRAM Please rate each of the following

Your experience as a NRC Research Associate in this federal Laboratory 1 (poor) to 10 (excellent)

10 Short-term value: development of knowledge, skills, and research productivity

Comments:

10 Long-term value: how your NRC Associateship award affected your career to date

Comments:

Administrative Support 1 (poor) to 10 (excellent)

9 Quality of the support you received from the federal Laboratory

10 Quality of the support you received from the NRC staff (Leave blank, if not applicable - e.g., NIST)

Comments on both/either:

18) PLEASE PROVIDE ANY SUGGESTIONS FOR PROGRAM IMPROVEMENT

US Postal Service mailing address
Research Associateship Programs
National Research Council
500 Fifth Street, NW [GR 322A]
Washington, DC 20001

n:\AO Forms
ID#

fax
202 - 334 - 2759
rap@nas.edu
website
www.national-academies.org/rap

NRC ASSOCIATESHIP OFFICE
cc:

Express Delivery address
Research Associateship Programs
National Research Council
2001 Wisconsin Avenue, NW [GR 322A]
Washington, DC 20007

Rev. 08/2002
cost-center #

FINAL REPORT

Enter information electronically in Layout view.

Return this form directly to the NRC as an E-mail attachment, or print out and mail or fax.

1) Associate Last or Family Name Nair	First Name Lalitha	M.I. PV
2) FORWARDING Address (to which your tax statement will be mailed) F 62, CSIR Scientist Apartment, Maharani Bagh, New Delhi 110065, India	FORWARDING Phone(s) and E-Mail (if known) Phone: 91-11-6917555 Phone: 91-11-6325129 E-mail: Lalithapv@hotmail.com	
3) Today's Date September 24, 2002	Dates of Tenure from October 11, 2000 to October 10, 2002	
4) Agency AMRMC	Laboratory or NASA Center WRAIR	Division / Branch / Directorate CD & I, Immunology

5) NAME OF RESEARCH ADVISER

David E Lanar

6) TITLE OF RESEARCH PROPOSAL

Cloning, Expression and Immunological Characterization of AMA-1 and its Subdomain Fragments in Bacteria

7) SUMMARY OF RESEARCH DURING TENURE Itemize significant findings in concise form, utilizing key concepts/words.

- 1) Worked in the development of the purification of an important malaria vaccine target antigen PfAMA1/E that (99% pure) was scaleable and transferable to GMP facility, and that induced high titre growth inhibitory antibodies in rabbits.
- 2) Purification protocol was used in the writing of Batch Production Record BPR-480, entitled "Preparation of a Bulk Lot Recombinant *P. falciparum* AMA1/E Protein Expressed in *Escherichia coli*, Origami Strain.
- 3) The data from this analysis will be part of an IND application to the FDA to use this protein as a vaccine in humans.
- 4) Cloned, expressed, purified and immunologically characterized all six subdomain constructs from ectodomain of AMA-1 in bacteria. It enabled to fine map the immunodominant regions of the whole molecule.
- 5) Erythrocyte binding activity of AMA-1 and the subdomain fragments is established from this study. These data may help to develop better AMA-1 based constructs for vaccine study.

8) RESEARCH IN PROGRESS Describe in no more than 100 words.

Cloned and expressed all the six subdomain fragments of AMA-1 ectodomain in bacteria, purified in order to fine map the immune responses. The purified double domains have generated high titre antibodies in rabbits that recognized the native parasite in IFA and recognized the parasite AMA-1 in Western blot experiments. Domain I+II generated most of the growth inhibitory antibodies on a growth inhibition/invasion assay in vitro, suggesting that this region is most important in AMA-1 ectodomain. Also, most of the immune responses towards the ectodomain are localized in the domain II, though this region alone is not enough to generate inhibitory antibodies. AMA-1 and all six subdomains, I+II, II+III, I+III, I, II and III have shown to have erythrocyte binding activity to human RBC. Immunization with single domains is being done. Projects on D I+II crystal structure elucidation and mapping of monoclonal antibodies are also in progress, in collaboration.

9) PUBLICATIONS AND PAPERS RESULTING FROM NRC ASSOCIATESHIP RESEARCH

Provide complete citations: author(s), title, full name of journal, volume number, page number(s), and year of publication.

a) Publications in peer-reviewed journals

1. Purification and characterisation of the refolded ectodomain of the Apical Membrane Antigen-1 of Plasmodium falciparum expressed in *Escherichia coli*. S Dutta, P V Lalitha, L A Ware, A Barbosa, JK Moth, MA Vassel, S Kitov, N Kolodny, J D Haynes and D E Lanar, *Infection and Immunity*, 2002, 70(6), 3001-10.

b) Books, book chapters, other publications

c) Manuscripts in preparation, manuscripts submitted

1. Lalitha PV, Ware LA, Barbosa A, Dutta S, Moch K, Haynes JD, Lanar DE. Protective antibody responses to AMA-1 is directed towards D I+II: Results from Analysis of Cloning, expression, purification and immunological characterisation of refolded Plasmodium falciparum AMA-1 Subdomain fragments in E. coli.

10 PATENT OR COPYRIGHT APPLICATIONS RESULTING FROM NRC ASSOCIATESHIP RESEARCH

Provide titles, inventors, and dates of applications.

1. Process for purification of recombinant Plasmodium falciparum AMA-1 from E. coli . D E Lanar, S Dutta, L A Ware and Lalitha P V. Filed a Provisional U.S. Patent Application, filing date: March 26, 2001.

11) PRESENTATIONS AT SCIENTIFIC MEETINGS OR CONFERENCES

Provide complete references: author(s), title, abstract/proceeding citation, meeting name and location.

International

1. Barbosa A, Wood CL, Lalitha PV, Tighe JJ, Ware LA, Dutta S, Haynes JD, Moch JK, Bowden RA, Lanar DE, Heppner DG , Kellerman SA, Green LL , Production of Human Monoclonal Antibodies to the Plasmodium falciparum AMA-1 Protein, Paper to be presented at 51st ASTMH Meeting to be held at Denver, CO, USA during 10-14 Nov 2002.
2. Haynes JD, Lanar DE, Dutta S, Lalitha PV, Barbosa A, Darko CA, Angov E, Lyon JA, Narum DL, Sim BKL, Moch JK, Malaria Growth Inhibition Assays (GIA) in Vaccine Candidate Evaluation: Roles of Suspension GIA and Reversal of Inhibition by Antigen, Paper to be presented at 51st ASTMH Meeting to be held at Denver, CO, USA during 10-14 Nov 2002.
3. Cloning, Expression, Purification and Immunogenicity of Refolded Regions of Plasmodium falciparum AMA-1 Ectodomain in E. coli, Lalitha PV, Ware LA, Barbosa A, Dutta S, Moch JK, Vassell M, Haynes JD, and Lanar DE, Paper to be presented at 16th Annual Symposium of the Protein Society to be held in August 17-21, 2002 San Diego, California.
4. Lalitha PV, Ware LA, Barbosa A, Dutta S, Moch K, Vassell M Haynes JD, Lanar DE. Immunological characterisation of bacterially expressed Plasmodium falciparum AMA-1 Subdomain fragments. Proceedings of Keystone Symposia, Keystone, Colorado, USA, 3-8 March, 2002.
5. Dutta S, Barbosa A, Ware LA, Fileta BB, Lalitha PV, Moch JK, Vassell MA, Haynes JD, Lanar DE. Biophysical, biochemical and immunological comparison of a refolded malaria vaccine candidate Pf AMA-1/E, produced under GMP environment in two bacterial hosts. Proceedings of "Experimental Biology- Translating the Genome" during April 20-24, 2002, New Orleans, Louisiana, USA.
6. Lalitha PV , Ware LA, Moch K, Haynes JD, Dutta S, Barbosa A, Lanar DE. Expression, purification and immunological analysis of plasmodium falciparum ama-1 subdomains in bacteria, Proceedings of 50th ASTMH Annual Meeting, Atlanta, Georgia, USA during 11-15, Nov 2001
7. Dutta S, Lalitha PV, Ware LA, Barbosa A, Moch K, Haynes JD, Vassell MR, Lanar DE. Purification and characterization of a refolded plasmodium falciparum apical membrane antigen-1 ectodomain produced under cGMP conditions for clinical use, Proceedings of 50th ASTMH Annual Meeting, Atlanta, Georgia, USA during 11-15, Nov 2001.

Domestic

12) SEMINARS OR LECTURES DELIVERED AT UNIVERSITIES AND/OR INSTITUTES Include dates, names and locations of seminars.

1. Cloning, Expression and Immunological Characterization of Apical Membrane Antigen (AMA-1) Subdomain Fragments from P. falciparum, Immunology Department, CD&I, Walter Reed Army Institute of Research, on 11 September 2002.
2. Cloning, Expression and Immunological Studies of Apical Membrane Antigen (AMA-1) and its Subdomain Fragments from P. falciparum, Seminar during NRC Meeting at WRAIR during April 2002

13) PROFESSIONAL AWARDS RECEIVED DURING TENURE

Young Scientist Project, Department of Science and Technology, New Delhi, India for a Project entitled Structural and functional characterisation of some important malarial blood stage vaccine target antigens from Plasmodium falciparum Indian isolates.

14) NEW POSITION TITLE

Research Scientist

15) NEW POSITION ORGANIZATION Provide name and address of organization.

Tentatively-Department of Science and Technology, New Delhi (Sponsors); Exact laboratory is to be decided in two months.

16) NEW POSITION STATUS / CATEGORY Please indicate only one.

Remain at Host Agency as Permanent Employee
 Remain at Host Agency as Contract/Temporary Employee
Abbreviate Host Laboratory/Center
 Research Position at Another US Government Laboratory

Administrative Position at US Government Laboratory
 Research Position at Foreign Government Laboratory

Research/Teaching at US College/University
 Research/Teaching at Foreign College/University
 Research/Administration in Industry
 Research/Administration in Non-Profit Organization

Postdoctoral Research
 Self Employed
 Other: specify

17) **APPRAISAL OF THE ASSOCIATESHIP PROGRAM** Please rate each of the following on a scale of 1 (poor) to 10 (excellent).

Your experience as a NRC Research Associate in this federal Laboratory

7 Short-term value: development of knowledge, skills, and research productivity

Comments:

I had the freedom to choose my project, plan and execute the way I wanted; hard work and earlier experience in this field helped me a lot to be very productive.

8 Long-term value: how your NRC Associateship award affected your career to date

Comments:

It was really a good exposure, it helped me to get more confidence in my abilities to do research. I could collaborate with some other projects/ laboratories such as Crystal structure elucidation of D I+II of AMA-1(BSI Proteomics Corporation, Gaithersburg, MD), Mapping of human monoclonal antibodies (Arnoldo Barbosa, WRAIR ; Medarex Corporation etc.) These experiences certainly helped me to improve my skills and will help to work more effectively on my return to India.

Administrative Support

9 Quality of the support you received from the federal Laboratory

10 Quality of the support you received from the NRC staff

Comments:

I am extremely thankful for the liberal support I received from NRC staff both from my Institute (Dr Sara Rothman's office) and also from Washington DC office. I never had any difficulty in finding solutions to my tiny problems.

18) **PLEASE PROVIDE ANY SUGGESTIONS FOR PROGRAM IMPROVEMENT**

US Postal Service mailing address
Research Associateship Programs
National Research Council
500 Fifth Street, NW [GR 322A]
Washington, DC 20001

n:AO Forms
ID#

fax
202 - 334 - 2759
rap@nas.edu

website
www.national-academies.org/rap

NRC ASSOCIATESHIP OFFICE
cc:

Express Delivery address
Research Associateship Programs
National Research Council
2001 Wisconsin Avenue, NW [GR 322A]
Washington, DC 20007

Rev. 10/2001
cost-center #

FINAL REPORT

Enter information electronically in Layout view.

Return this form directly to the National Academies as an E-mail attachment, or print out and mail or fax.

1) Associate Last or Family Name Savranksy	First Name Vladimir	M.I. M
2) FORWARDING Address (to which your tax statement will be mailed) 5325 Randolph Rd. #2, Rockville, MD 20852	FORWARDING Phone(s) and E-Mail (if known) Phone: (301) 230-0035 Phone: (240) 476-6774 E-mail: vsavranksy@yahoo.com	
3) Today's Date February 3, 2003	Dates of Tenure from February 12, 2001 to February 11, 2003	
4) Agency AMRMC	Laboratory or NASA Center WRAIR	Division / Branch / Directorate Experimental Pathology

5) Name of Research Associateship Programs Adviser
Jeenan Tseng, PhD

6) TITLE OF RESEARCH PROPOSAL

Mucosal Immune Response to Staphylococcal Enterotoxin B (SEB) Mutants Cloned into Lactobacillus casei

7) SUMMARY OF RESEARCH DURING TENURE Itemize significant findings in concise form, utilizing key concepts/words.

- 1) Developing the new murine intranasal SEB toxic shock model.
- 2) Screening various SEB mutant proteins for superantigenicity, toxicity, and selecting safe mucosal vaccine candidate.
- 3) Studying immunogenicity and protective properties of selected candidates.
- 4) Developing a novel mucosal vaccine against SEB intoxication
- 5)

8) RESEARCH IN PROGRESS Describe in no more than 100 words.

Developing and describing histopathology of murine TSST-1 induced toxic shock model.

9) PUBLICATIONS AND PAPERS RESULTING FROM NATIONAL ACADEMIES ASSOCIATESHIP RESEARCH

Provide complete citations: author(s), title, full name of journal, volume number, page number(s), and year of publication.

a) Publications in peer-reviewed journals

1. V. Savranksy, V. Rostapshov, D. Pinelis, Y. Polotsky, S. Korolev, K. Fegeding, J. Komisar, and J. Tseng. Murine Lethal Toxic Shock Caused by Intranasal Administration of Staphylococcal Enterotoxin B (2003). Toxicologic Pathology, 31(4).

b) Books, book chapters, other publications

c) Manuscripts in preparation, manuscripts submitted

1. D. Pinelis, V. Savranksy, S. Korolev, J. Komisar, K. Fegeding, and J. Tseng. Immunogenicity of the Histidine-to-Tyrosine Staphylococcal Enterotoxin B Mutant in C3H/HeJ Mice. (Submitted to Vaccine)
2. V. Savranksy, D. Pinelis, S. Korolev, J. Komisar, B. Ionin, K. Fegeding, and J. Tseng. Novel Intranasal Vaccine Candidate Protects Mice against Lethal Staphylococcal Enterotoxin B Challenge (Manuscript in preparation)
3. S. Korolev, D. Pinelis, V. Savranksy, J. Komisar, P. Vogel, and K. Fegeding. Toxicity of the Staphylococcal Enterotoxin B (SEB) Mutants with Histidine-to-Tyrosine Substitutions. (Submitted to Toxicology)

Provide titles, inventors, and dates of applications.

n/a

11) PRESENTATIONS AT SCIENTIFIC MEETINGS OR CONFERENCES

Provide complete references: author(s), title, abstract/proceeding citation, meeting name and location.

International

Experimental Pathology 2002, "Translating the Genome", New Orleans, LA, April 19-24, 2002

1. Savransky V, Pinelis D, Fegeding K, Polotsky Y, Komisar J, Tseng J. Lethal Toxic Shock Induced by Intranasal Inoculation of Staphylococcal Enterotoxin B (SEB) in Unmanipulated Mice. FASEB Journal. 2002; 16(5): A967.
2. Korolev S, Pinelis D, Savransky V, Fegeding K, Komisar J, Tseng J. Superantigenicity and Toxicity of Staphylococcal Enterotoxin B (SEB) Mutants with Histidine-to-Tyrosine Substitution. FASEB Journal. 2002; 16(5): A680.

Domestic

12) SEMINARS OR LECTURES DELIVERED AT UNIVERSITIES AND/OR INSTITUTES Include dates, names and locations of seminars.

n/a

13) PROFESSIONAL AWARDS RECEIVED DURING TENURE

n/a

14) POST-TENURE POSITION TITLE

n/a

15) POST-TENURE ORGANIZATION Provide name and address of organization.

n/a

16) POST-TENURE POSITION STATUS / CATEGORY Please indicate only one.

Remain at Host Agency as Permanent Employee
 Remain at Host Agency as Contract/Temporary Employee
Abbreviate Host Laboratory/Center _____
 Research Position at Another US Government Laboratory
 Administrative Position at US Government Laboratory
 Research Position at Foreign Government Laboratory

Research/Teaching at US College/University
 Research/Teaching at Foreign College/University
 Research/Administration in Industry
 Research/Administration in Non-Profit Organization
 Postdoctoral Research
 Self Employed
 Other: specify n/a

17) APPRAISAL OF RESEARCH ASSOCIATESHIP PROGRAM Please rate each of the following on a scale of 1 (poor) to 10 (excellent).

Your experience as a National Academies Research Associate in this federal Laboratory

10 Short-term value: development of knowledge, skills, and research productivity
Comments:

8 Long-term value: how the National Academies Associateship award affected your career to date
Comments:

Administrative Support

7 Quality of the support you received from the federal Laboratory

10 Quality of the support you received from the Research Associateship Programs staff (Leave blank, if not applicable— e.g., NIST)
Comments:

I have received high quality administrative support from both Laboratory and RAP staff, including information, accomadation, and relocation.

18) PLEASE PROVIDE ANY SUGGESTIONS FOR PROGRAM IMPROVEMENT.

US Postal Service mailing address
Research Associateship Programs
The National Academies

fax
202 – 334 – 2759
rap@nas.edu

Express Delivery address
Research Associateship Programs
The National Academies

THE NATIONAL ACADEMIES

Advisers to the Nation on Science, Engineering, and Medicine

National Research Council

Associateship Programs

FINAL REPORT

Enter information electronically in Layout view.

Return this form directly to the NRC as an E-mail attachment, or print out and mail or fax.

1) Associate Last or Family Name	First Name	M.I.
Zhu	Shuren	
2) FORWARDING Address (to which your tax statement will be mailed)	FORWARDING Phone(s) and E-Mail (if known) Phone: 301-871-0032 Phone: 301-319-9645 E-mail: shuren.zhu@na.amedd.army.mil	
14110 Grand Pre Road #33, Silver Spring, MD 20906		
3) Today's Date	Dates of Tenure	
October 7, 2002	from November 1, 2001	to October 31, 2002
4) Agency	Laboratory or NASA Center	Division / Branch / Directorate
AMRMC	WRAIR	Experimental Therapeutics

5) NAME OF RESEARCH ADVISER

Ai Jeng Lin, Ph.D.

6) TITLE OF RESEARCH PROPOSAL

Design and Synthesis of Cysteine Proteinase Inhibitors as Potential Antimalarial Therapeutics

7) SUMMARY OF RESEARCH DURING TENURE Itemize significant findings in concise form, utilizing key concepts/words.

- 1) A novel class of peptidomimetic antimalarial agents has been discovered.
- 2) Compounds exhibited potent in vitro and in vivo activity against malarial parasites.
- 3)
- 4)
- 5)

8) RESEARCH IN PROGRESS Describe in no more than 100 words.

A novel class of peptidomimetic antimalarial agents has been discovered. The core structure of these compounds consists of a substituted 5-aminopyrimidone ring and a Michael acceptor side chain. These compounds exhibited potent in vitro growth inhibitory activity against both chloroquine sensitive (D-6) and chloroquine resistant (W-2) Plasmodium falciparum clones. This class of compounds exhibited weak to insignificant in vitro cytotoxicity against neuronal, macrophage, and colon cell lines. A scale-up synthesis has also been performed, gram quantities of these compounds has been made available for in vivo anti-malarial studies. Some selected compounds exhibited in vivo antimalarial activity at 40-160 mg/kg dosages.

9) PUBLICATIONS AND PAPERS RESULTING FROM NRC ASSOCIATESHIP RESEARCH

Provide complete citations: author(s), title, full name of journal, volume number, page number(s), and year of publication.

a) Publications in peer-reviewed journals

Shuren Zhu, Thomas H. Hudson, Dennis E. Kyle, and Ai J. Lin, Synthesis and In Vitro Studies of Novel Pyrimidinyl Peptidomimetics as Potential Antimalarial Therapeutic Agents. Journal of Medicinal Chemistry, 2002, 45, 3491-3496.

b) Books, book chapters, other publications

None

c) Manuscripts in preparation, manuscripts submitted

None

10 PATENT OR COPYRIGHT APPLICATIONS RESULTING FROM NRC ASSOCIATESHIP RESEARCH

Provide titles, inventors, and dates of applications.

None

11 PRESENTATIONS AT SCIENTIFIC MEETINGS OR CONFERENCES

Provide complete references: author(s), title, abstract/proceeding citation, meeting name and location.

International

None

Domestic

Synthesis of Pyrimidinyl Peptidomimetics As Potential Antimalarial Therapeutics, Shuren Zhu and Ai J. Lin, presented at the 34th American Chemical Society Middle Atlantic Regional Meeting, Towson, Maryland, 2001.

12) SEMINARS OR LECTURES DELIVERED AT UNIVERSITIES AND/OR INSTITUTES *Include dates, names and locations of seminars.*

None

13) PROFESSIONAL AWARDS RECEIVED DURING TENURE

None

14) NEW POSITION TITLE

Research Associate

15) NEW POSITION ORGANIZATION *Provide name and address of organization.*

WRAIR, 503 Robert Grant Avenue, Silver Spring, Maryland 20910

16) NEW POSITION STATUS / CATEGORY *Please indicate only one.*

Remain at Host Agency as Permanent Employee
 Remain at Host Agency as Contract/Temporary Employee
Abbreviate Host Laboratory/Center **WRAIR**
 Research Position at Another US Government Laboratory
 Administrative Position at US Government Laboratory
 Research Position at Foreign Government Laboratory

Research/Teaching at US College/University
 Research/Teaching at Foreign College/University
 Research/Administration in Industry
 Research/Administration in Non-Profit Organization
 Postdoctoral Research
 Self Employed
 Other: specify _____

17) APPRAISAL OF THE ASSOCIATESHIP PROGRAM *Please rate each of the following on a scale of 1 (poor) to 10 (excellent).*

Your experience as a NRC Research Associate in this federal Laboratory

10 Short-term value: development of knowledge, skills, and research productivity
Comments:

10 Long-term value: how your NRC Associateship award affected your career to date
Comments:

Administrative Support

10 Quality of the support you received from the federal Laboratory
10 Quality of the support you received from the NRC staff
Comments:

18) PLEASE PROVIDE ANY SUGGESTIONS FOR PROGRAM IMPROVEMENT


10/7/2002

US Postal Service mailing address
Research Associateship Programs
National Research Council
500 Fifth Street, NW [GR 322A]
Washington, DC 20001
n:\AO Forms
ID#

fax
202 - 334 - 2759
rap@nas.edu
website
www.national-academies.org/rap
NRC ASSOCIATESHIP OFFICE
cc:

Express Delivery address
Research Associateship Programs
National Research Council
2001 Wisconsin Avenue, NW [GR 322A]
Washington, DC 20007
Rev. 10/2001
cost-center #